Last reviewed · How we verify
placebo BID
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
At a glance
| Generic name | placebo BID |
|---|---|
| Also known as | placebo |
| Sponsor | Inotek Pharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-therapeutic agent administered in blinded studies to serve as a control comparator. Any observed effects are attributable to the placebo effect—psychological and contextual factors rather than direct drug action. BID (twice daily) refers only to the dosing schedule.
Approved indications
Common side effects
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |